May 19, 2016
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Video Categories: 2018 ASCO Insights, Biomarkers, and Video LibraryDr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Related Videos
November 10, 2012
PMO Interview with the Innovator Series: Volume 4
Tom Reynolds, Chief Medical Officer of Seattle Genetics, offers a definition of personal medicine in this new video series from Personalized Medicine in Oncology.
April 14, 2015
Managing Costs in Oncology Care
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.